Welcome to LookChem.com Sign In|Join Free

CAS

  • or

133242-63-4

Post Buying Request

133242-63-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

133242-63-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 133242-63-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,2,4 and 2 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 133242-63:
(8*1)+(7*3)+(6*3)+(5*2)+(4*4)+(3*2)+(2*6)+(1*3)=94
94 % 10 = 4
So 133242-63-4 is a valid CAS Registry Number.

133242-63-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-hydroxyphenyl)propionate

1.2 Other means of identification

Product number -
Other names 4S- (2,2-DIMETHYL-1,3-DIOXYCYCLOPENTANE -4-YL)METHYL-3-(4-HYDROXYBENZENEYL)PROPIONATE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:133242-63-4 SDS

133242-63-4Relevant articles and documents

Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101

Iguchi,Iwamura,Nishizaki,Hayashi,Senokuchi,Kobayashi,Sakaki,Hachiya,Ichioka,Kawamura

, p. 1462 - 1469 (2007/10/02)

A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 133242-63-4